Stockreport

UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform [Yahoo! Finance]

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF a Buy rating and a $35 price target, citing the company's transition from a China-centric commercial strategy to a global innovation powerhouse. The firm views Zai Lab L [Read more]